Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation is a biopharmaceutical company specializing in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeting the unmet needs of the aging male population in developed economies. The company's lead drug candidate, Fexapotide Triflutate (FT), is a novel injectable therapy for benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer. FT has completed Phase 3 development in more than 70 clinical centers in the United States, involving over 1,700 patients across the entire clinical development program. The company is preparing to file for approval in major economies, including the United States and Europe. In addition to FT, Nymox offers NicAlert and TobacAlert, simple test strips for determining smoking status using saliva or urine samples. The company is headquartered in Nassau, Bahamas, and has office locations in Canada, the United States, and Switzerland. It is in the process of relocating its headquarters from the Bahamas to Switzerland. Nymox is publicly traded and provides investor information through SEC filings, annual reports, and press releases. Its research focuses on addressing significant unmet clinical needs in elderly men, particularly for BPH and early-stage prostate cancer.

Nymox Pharmaceutical Corporation is a biopharmaceutical company focused on the research and development of therapeutics and diagnostics, particularly for the aging male population. The company's lead drug candidate, Fexapotide Triflutate (FT), is a novel injectable therapy for benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer. FT has completed Phase 3 development in more than 70 clinical centers in the United States, involving over 1,700 patients during the entire clinical development program. The company is preparing to file for approval in major economies, including the United States and Europe. In addition, Nymox is developing FT for early-stage, non-aggressive prostate cancer, with a Phase II trial in the United States in 147 men demonstrating long-term clinical benefits, including significant delay in disease progression compared to controls. The company is headquartered in Nassau, Bahamas, and has office locations in Canada, the United States, and Switzerland. It is in the process of relocating its headquarters from the Bahamas to Switzerland. Nymox also offers NicAlert and TobacAlert, simple test strips for determining smoking status. The company is publicly traded and provides investor information through SEC filings, annual reports, and press releases. Recent news includes the availability of Nymozarfex (TM) for prostate treatments for medical tourists in collaboration with the Global Alliance.

• Nymox's Nymozarfex (TM) Newly Available For Prostate Treatments for Medical Tourists in Collaboration with the Global Alli...

Developing a novel, safe, efficacious and long-lasting injectable therapy for BPH and early-stage prostate cancer, with a focus on unmet needs of the aging male population.

• Fexapotide Triflutate

  A protein injectable for benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer. It is designed to be administered in the urologist's office in a simple injection that takes a few minutes. FT is a new molecular entity that safely targets prostate glandular cells that have proliferated in BPH. FT works by inducing apoptosis (programmed cell death) which selectively removes cells in the enlarged BPH prostate gland, and is also useful in removing low-grade localized early-stage prostate cancers. In large clinical trials involving over 1,700 men there have been minimal side effects.

• NicAlert

  A simple, cost-effective test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample. NicAlert can help smokers and family members get a more accurate measure of smoking; parents check whether their teenaged children are smoking; teachers and high school coaches test high school athletes for smoking or other tobacco product use; verify smoking status for insurance applications; and test subjects in tobacco research studies.

• TobacAlert

  A test for determining smoking status, similar to NicAlert.

1. 1Nymox Pharmaceutical Corporation | NYMOXnymox.com
2. 2Corporate | NYMOXnymox.com
3. 3Products | NYMOXnymox.com
4. 4Company Presentation | NYMOXnymox.com
5. 5Nymox (Canada) - Wikidatawikidata.org